

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2023/003995 A8

(43) International Publication Date
26 January 2023 (26.01.2023)

- (51) **International Patent Classification:**
C12N 15/113 (2010.01) A61K 31/713 (2006.01) SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- (21) **International Application Number:** PCT/US2022/037794 **Published:**
— with international search report (Art. 21(3))
- (22) **International Filing Date:** 21 July 2022 (21.07.2022) **(48) Date of publication of this corrected version:**
09 November 2023 (09.11.2023)
- (25) **Filing Language:** English **(15) Information about Correction:**
see Notice of 09 November 2023 (09.11.2023)
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/224,901 23 July 2021 (23.07.2021) US
63/293,851 27 December 2021 (27.12.2021) US
- (71) **Applicant: ALNYLAM PHARMACEUTICALS, INC.**
[US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US).
- (72) **Inventors: AKINC, Akin;** 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). **ZUBER, Jeffrey;** 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US).
- (74) **Agent: ZACHARAKIS, Maria, Laccotripe et al.;** McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

(54) **Title:** BETA-CATENIN (CTNNB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

(57) **Abstract:** The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the beta-catenin (CTNNB1) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CTNNB1 gene and to methods of preventing and treating a CTNNB1-associated disorder, e.g., cancer, e.g., hepatocellular carcinoma.

WO 2023/003995 A8